secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001628280-26-028386
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crescent Biopharma Q1 net loss $23.3M; cash $189.2M funds ops into 2028
-----------------------------------------------------------------------

- Net loss $23.3M ($0.70/sh) vs $15.1M ($19.63/sh) in Q1 2025; revenue $1.0M from Kelun-Biotech license.
- R&D expenses $17.9M (up 69% YoY) on CR-001/CR-002 development; G&A $7.9M (up 119% YoY).
- Cash $189.2M as of March 31, 2026; expected to fund operations into 2028.
- CR-001 ASCEND trial enrollment ongoing; proof-of-concept data expected Q1 2027.
- CR-002 IND submission on track for mid-2026; clinic entry H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000162828026028386/0001628280-26-028386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000162828026028386/cbio-20260429.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-028386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer